A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study.

Richard F. Riedel,Karla V. Ballman,Yao Lu,Steven Attia,Elizabeth T. Loggers,Kristen N. Ganjoo,Michael B. Livingston,Warren Chow,Jennifer A. Wright,John Ward,Daniel A. Rushing,Scott Heitaka Okuno,Damon R. Reed,David A. Liebner,Vicki L. Keedy,Leo Mascarenhas,Lara E. Davis,Christopher W. Ryan,Denise K. Reinke,Robert G. Maki

A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study.

2018

11505Background: Pazopanib, a multi-targeted tyrosine kinase inhibitor, has shown activity in various soft tissue sarcomas. Activity in liposarcoma, however, is limited. Regorafenib is a multi-kina...

Keywords:

Placebo
Regorafenib
Phases of clinical research
Physical therapy
Medicine
Liposarcoma
Gastroenterology
Tyrosine-kinase inhibitor
treatment refractory
Internal medicine
Soft tissue
Pathology
Pazopanib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations